Brought to you by 
Sprint partners tumor metabolism program with Bayer; deal ends
01 Feb 2023
Executive Summary
Sprint Bioscience AB licensed Bayer HealthCare Pharmaceuticals AG global rights to develop and sell a tumor metabolism inhibitor that's in early-stage studies for cancer. Bayer also has diagnostic rights.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sprint partners tumor metabolism program with Bayer; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice